Table 3 Association between NAT1 and NAT2 and bladder cancer risk among women and men
From: Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2genes and bladder cancer risk in men and women
| Â | NHS | HPFS | ||||||
|---|---|---|---|---|---|---|---|---|
Genotype | Case, n (%) | Control, n (%) | OR (95% CI)1 | OR (95% CI)2 | Case, n (%) | Control, n (%) | OR (95% CI)1 | OR (95% CI)2 |
NAT2 genotype | ||||||||
Rapid and intermediate acetylators | 20 (31.8) | 1007 (37.9) | 1.00 ref | 1.00 ref | 53 (42.7) | 463 (38.2) | 1.00 ref | 1.00 ref |
Slow acetylator | 43 (68.3) | 1645 (62.0) | 1.31 (0.77, 2.24) | 1.33 (0.77, 2.31) | 71 (57.2) | 750 (61.8) | 0.81 (0.55, 1.19) | 0.78 (0.53, 1.15) |
Rapid acetylator | 2 (3.2) | 131 (4.9) | 1.00 ref | 1.00 ref | 5 (3.9) | 72 (5.6) | 1.00 ref | 1.00 ref |
Intermediate acetylator | 18 (28.6) | 876 (33.0) | 1.34 (0.31, 5.86) | 1.29 (0.29, 5.65) | 48 (37.5) | 391 (30.3) | 1.84 (0.70, 4.83) | 1.94 (0.73, 5.12) |
Slow acetylator | 43 (68.3) | 1645 (62.0) | 1.70 (0.41, 7.10) | 1.67 (0.40, 6.98) | 71 (57.3) | 750 (61.8) | 1.38 (0.53, 3.58) | 1.39 (0.53, 3.60) |
NAT1 genotype | ||||||||
Any allele | 48 (73.9) | 139 (67.2) | 1.00 ref | 1.00 ref | 84 (65.6) | 179 (65.8) | 1.00 ref | 1.00 ref |
*10 carrier | 17 (26.2) | 68 (32.9) | 0.76 (0.40, 1.42) | 0.77 (0.41, 1.44) | 44 (34.4) | 93 (33.9) | 1.06 (0.68, 1.66) | 1.07 (0.68, 1.70) |
*4/*4 | 39 (70.9) | 116 (65.2) | 1.00 ref | 1.00 ref | 71 (65.7) | 149 (64.2) | 1.00 ref | 1.00 ref |
*10/*4 + *10/*10 | 16 (29.1) | 62 (34.8) | 0.79 (0.41, 1.54) | 0.81 (0.42, 1.57) | 37 (34.3) | 83 (35.5) | 0.98 (0.60, 1.59) | 1.00 (0.61, 1.65) |